Outcomes and Trends

Outcomes data for hematopoietic cell transplants (bone marrow, PBSC, or cord blood transplants — BMT) available here include data on outcomes of autologous and allogeneic transplants collected by the Center for International Blood and Marrow Transplant Research^® (CIBMTR). Also available are CIBMTR data on trends in transplantation and data on unrelated donor and cord blood transplants from the National Marrow Donor Program^® (NMDP), which operates Be The Match^®. Analyses of NMDP transplants between 1987-2010 for all major diseases for which transplant is indicated have shown that in each disease category, survival has consistently, and sometimes dramatically, improved over time. For details, see Improvements in Unrelated Donor Transplantation.

Transplant outcomes by disease
Acute lymphoblastic leukemia
Figure 1. (CIBMTR data) View larger version	Probability of survival after HLA-identical sibling transplants for ALL, age <20 years, 2000-2010, by disease status. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.

Figure 2. (CIBMTR data) View larger version	Probability of survival after HLA-identical sibling transplants for ALL, age ≥20 years, 2000-2010, by disease status. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.

Figure 3. (NMDP data) View larger version	ALL: Survival of adult marrow transplant patients by disease stage, unrelated donor transplants facilitated by the NMDP, 2000-2009. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Acute Lymphoblastic Leukemia (ALL) — NMDP Transplant Outcomes.

Figure 4. (NMDP data) View larger version	ALL: Survival of pediatric marrow transplant patients by disease stage, unrelated donor transplants facilitated by the NMDP, 2000-2009. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Acute Lymphoblastic Leukemia (ALL) — NMDP Transplant Outcomes.

Figure 5. (NMDP data) View larger version	ALL: Survival of adult PBSC transplant patients by disease stage, unrelated donor transplants facilitated by the NMDP, 2000-2009. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Acute Lymphoblastic Leukemia (ALL) — NMDP Transplant Outcomes.
Acute myelogenous leukemia
Figure 6. (CIBMTR data) View larger version	Probability of survival after HLA-identical sibling transplants for AML, 2000-2010, by disease status. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.

Figure 7. (CIBMTR data) View larger version	Probability of survival after autologous transplants for AML, 2000-2010, by disease status. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.

Figure 8. (CIBMTR data) View larger version	Probability of survival after HLA identical sibling transplants for AML age <20 years, 2000-2010, by disease status. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.

Figure 9. (NMDP data) View larger version	AML: Survival of adult marrow transplant patients by disease stage, unrelated donor transplants facilitated by the NMDP, 2000-2009. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Acute Myelogenous Leukemia — NMDP Transplant Outcomes.

Figure 10. (NMDP data) View larger version	AML: Survival of pediatric marrow transplant patients by disease stage, unrelated donor transplants facilitated by the NMDP, 2000-2009. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Acute Myelogenous Leukemia — NMDP Transplant Outcomes.

Figure 11. (NMDP data) View larger version	AML: Survival of adult PBSC transplant patients by disease stage, unrelated donor transplants facilitated by the NMDP, 2000-2009. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Acute Myelogenous Leukemia — NMDP Transplant Outcomes.

Figure 12. (NMDP data) View larger version	AML: Survival of transplant patients >55 years old, PBSC and marrow, by disease stage, unrelated donor transplants facilitated by the NMDP, 2000-2009. For discussion of these data, see Acute Myelogenous Leukemia — NMDP Transplant Outcomes.
Chronic myelogenous leukemia
Figure 13. (CIBMTR data) View larger version	Probability of survival after matched sibling donor transplants for CML, 1998-2010, by disease status and transplant year. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.

Figure 14. (NMDP data) View larger version	CML: Survival of adult marrow transplant patients by disease stage, unrelated donor transplants facilitated by the NMDP, 2000-2009. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Chronic Myelogenous Leukemia (CML) — NMDP Transplant Outcomes.

Figure 15. (NMDP data) View larger version	CML: Survival of adult PBSC transplant patients by disease stage, unrelated donor transplants facilitated by the NMDP, 2000-2009. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Chronic Myelogenous Leukemia (CML) — NMDP Transplant Outcomes.
Myelodysplastic syndromes
Figure 16. (CIBMTR data) View larger version	Probability of survival after allogeneic transplants for myelodysplastic syndromes (MDS), 2000-2010, by disease status and donor type. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.

Figure 17. (NMDP data) View larger version	MDS: Survival of adult marrow transplant patients by WHO disease classification, unrelated donor transplants facilitated by the NMDP, 2000-2009. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Myelodysplastic Syndromes (MDS) — NMDP Transplant Outcomes.

Figure 18. (NMDP data) View larger version	MDS: Survival of adult PBSC transplant patients by WHO disease classification, unrelated donor transplants facilitated by the NMDP, 2000-2009. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Myelodysplastic Syndromes (MDS) — NMDP Transplant Outcomes.

Figure 19. (NMDP data) View larger version	MDS: Survival of adult marrow and PBSC transplant patients by age (18-54 yrs. or >55 yrs.), unrelated donor transplants facilitated by the NMDP, 2000-2009. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Myelodysplastic Syndromes (MDS) — NMDP Transplant Outcomes.

Figure 20. (NMDP data) View larger version	MDS: Survival of adult PBSC and marrow transplant patients by preparative regimen, unrelated donor transplants facilitated by the NMDP, 2000-2009. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Myelodysplastic Syndromes (MDS) — NMDP Transplant Outcomes.
Hodgkin/non-Hodgkin lymphoma
Figure 21. (CIBMTR data) View larger version	Probability of survival after autologous transplants for Hodgkin disease, 2000-2010, by disease status. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.

Figure 22. (CIBMTR data) View larger version	Probability of survival after autologous transplants for diffuse large B-cell lymphoma, 2000-2010, by disease status. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.

Figure 23. (CIBMTR data) View larger version	Probability of survival after autologous transplants for follicular lymphoma, 2000-2010, by disease status. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.

Figure 24. (CIBMTR data) View larger version	Probability of survival after HLA-identical sibling transplants for follicular lymphoma, 2000-2010, by disease status. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.

Figure 25. (CIBMTR data) View larger version	Probability of survival after HLA-identical sibling transplants for diffuse large B-cell lymphoma, 2000-2010, by disease status. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.

Figure 26. (NMDP data) View larger version	NHL: Survival of adult non-myeloablative transplant patients by cell source (PBSC or marrow), unrelated donor transplants facilitated by the NMDP, 2000-2009. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Non-Hodgkin Lymphoma (NHL) — NMDP Transplant Outcomes.

Figure 27. (NMDP data) View larger version	NHL: Survival of adult marrow transplant patients by NHL subclassification, unrelated donor transplants facilitated by the NMDP, 2000-2009. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Non-Hodgkin Lymphoma (NHL) — NMDP Transplant Outcomes.

Figure 28. (NMDP data) View larger version	NHL: Survival of adult PBSC transplant patients by NHL subclassification, unrelated donor transplants facilitated by the NMDP, 2000-2009. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Non-Hodgkin Lymphoma (NHL) — NMDP Transplant Outcomes.
Inherited immune/metabolic disorders
Figure 29. (NMDP data) View larger version	Inherited immune system disorders: Overall survival of pediatric marrow transplant patients with severe combined immunodeficiency (SCID) and Wiskott-Aldrich syndrome (WAS), unrelated donor transplants facilitated by the NMDP, 2000-2009. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Immune Deficiencies and Metabolic Disorders — NMDP Transplant Outcomes.

Figure 30. (NMDP data) View larger version	Inherited metabolic disorders: Survival of pediatric marrow transplant patients with Hurler syndrome, adrenoleukodystrophy (ALD)/metachromatic dystrophy (MLD), unrelated donor transplants facilitated by the NMDP, 2000-2009. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Immune Deficiencies and Metabolic Disorders — NMDP Transplant Outcomes.
Congenital anemias
Figure 31. (NMDP data) View larger version	Severe aplastic anemia: Survival of marrow transplant patients by age (adult or pediatric), unrelated donor transplants facilitated by the NMDP, 2000-2009. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Severe Aplastic Anemia & Fanconi Anemia — NMDP Transplant Outcomes.

Figure 32. (NMDP data) View larger version	Fanconi anemia: Survival of pediatric non-myeloablative/reduced-intensity marrow transplant patients, by cell source, unrelated donor transplants facilitated by the NMDP, 2000-2009. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Severe Aplastic Anemia & Fanconi Anemia — NMDP Transplant Outcomes.
Other disorders
Figure 33. (NMDP data) View larger version	Non-malignant diseases: Survival of pediatric transplant patients, by cell source, unrelated donor transplants facilitated by the NMDP, 2000-2009. Diseases include histiocytic disorders, thalassemia major, severe combined immunodeficiency (SCID) and other inherited immunodeficiencies, inherited metabolic disorders, inherited platelet disorders, autoimmune diseases, severe aplastic anemia, and Fanconi anemia.

Figure 34. (CIBMTR data) View larger version	Probability of survival after hematopoietic cell transplants for multiple myeloma, 2000-2010, by donor type. For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.

Diseases treated with transplant
Figure 35. (CIBMTR data) View larger version	Indications for hematopoietic stem cell transplants in the United States, 2010. For discussion of these data, see Diseases Treatable by Hematopoietic Cell Transplant.

Figure 36. (CIBMTR data) View larger version	Indications for hematopoietic stem cell transplants for age ≤20 years in the United States, 2010. For discussion of these data, see Diseases Treatable by Hematopoietic Cell Transplant.

Number of transplants facilitated by the NMDP
Figure 37. (NMDP data) View larger version	NMDP transplants by cell source, 1989-2012. (NMDP data are fiscal year data through September 30, 2012.) For discussion of these data, see Trends in Allogeneic Transplants.

Figure 38. (NMDP data) View larger version	NMDP transplants by cell source, pediatric recipients, 1989-2012. For discussion of these data, see Trends in Allogeneic Transplants.

Figure 39. (NMDP data) View larger version	NMDP transplants by patient diagnosis, malignant diseases, 2002-2012.

Figure 40. (NMDP data) View larger version	NMDP transplants by patient diagnosis, non-malignant disorders, 2002-2012.

Figure 41. (NMDP data) View larger version	NMDP transplants by recipient age and year, 2001-2012.

Sources of cells for transplant
Figure 42. (CIBMTR data) View larger version	Autologous stem cell sources by recipient age, 2001-2010. For discussion of these data, see Hematopoietic Cell Sources Tailored to the Patient.

Figure 43. (CIBMTR data) View larger version	Allogeneic stem cell sources by recipient age, 2001-2010. For discussion of these data, see Hematopoietic Cell Sources Tailored to the Patient.